Catalyst Pharmaceuticals, Inc. (CPRX) Stock Analysis
Healthcare · Biotechnology
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome... Read more
TrendMatrix rates Catalyst Pharmaceuticals, Inc. (CPRX) as Buy (Wait for Entry) with high confidence. The stock trades at $23.80 with +21.4% upside to the $28.90 price target. Overall score: 6.7/10 across 10 analysis dimensions. Reward/risk ratio: 2.2:1.
Passes 4/4 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags). Suitability: aggressive.
Investment Thesis
Fundamentals
Frequently Asked Questions
TrendMatrix rates Catalyst Pharmaceuticals, Inc. (CPRX) as Buy (Wait for Entry) with high confidence. Score 6.7/10. Entry target: $22.60.
Take-profit target: $28.90 (+21.4% upside). Reward/risk ratio: 2.2:1. Stop-loss: $21.50.
Catalyst Pharmaceuticals, Inc. trades at a P/E of 13.7 (forward 7.4). TrendMatrix value score: 8.5/10. Verdict: Buy (Wait for Entry).
14 analysts cover CPRX with a consensus score of 4.4/5. Average price target: $34.
What does Catalyst Pharmaceuticals, Inc. do?Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing...
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.